Blue Zone Wealth Advisors LLC Buys 17,364 Shares of Zoetis Inc. $ZTS

Blue Zone Wealth Advisors LLC lifted its stake in Zoetis Inc. (NYSE:ZTS) by 50.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 52,110 shares of the company’s stock after purchasing an additional 17,364 shares during the period. Blue Zone Wealth Advisors LLC’s holdings in Zoetis were worth $6,556,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of ZTS. Halbert Hargrove Global Advisors LLC increased its stake in shares of Zoetis by 496.6% in the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock valued at $25,000 after buying an additional 144 shares during the period. Global Wealth Strategies & Associates acquired a new position in shares of Zoetis during the fourth quarter valued at $25,000. Lodestone Wealth Management LLC acquired a new position in shares of Zoetis during the fourth quarter valued at $30,000. KERR FINANCIAL PLANNING Corp bought a new position in Zoetis in the third quarter valued at about $31,000. Finally, Holos Integrated Wealth LLC acquired a new stake in Zoetis in the fourth quarter worth about $32,000. Institutional investors own 92.80% of the company’s stock.

Zoetis Trading Down 0.1%

NYSE ZTS opened at $117.83 on Monday. The stock has a 50-day simple moving average of $122.71 and a 200 day simple moving average of $127.96. The company has a market capitalization of $49.74 billion, a PE ratio of 19.57, a P/E/G ratio of 1.80 and a beta of 0.98. The company has a current ratio of 3.03, a quick ratio of 1.94 and a debt-to-equity ratio of 2.71. Zoetis Inc. has a 12 month low of $113.29 and a 12 month high of $172.23.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.40 by $0.08. The firm had revenue of $2.39 billion for the quarter, compared to analysts’ expectations of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The company’s revenue was up 3.0% compared to the same quarter last year. During the same quarter last year, the business earned $1.40 earnings per share. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Research analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be paid a dividend of $0.53 per share. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 annualized dividend and a yield of 1.8%. Zoetis’s dividend payout ratio (DPR) is presently 35.22%.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. BTIG Research reissued a “buy” rating and set a $160.00 price objective on shares of Zoetis in a report on Thursday, February 26th. Wall Street Zen raised shares of Zoetis from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. UBS Group set a $136.00 price target on shares of Zoetis in a research report on Thursday, January 29th. Barclays initiated coverage on shares of Zoetis in a research note on Monday, December 8th. They set an “equal weight” rating and a $136.00 price target for the company. Finally, Morgan Stanley set a $160.00 price objective on shares of Zoetis in a research note on Thursday, December 18th. Six research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $152.91.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.